ADMETatlas — Peptide ADMET Evidence Atlas

All evidence

1,976records·25,806peptides

Showing reference-linked evidence across every ADMET endpoint. Pick a domain or endpoint in the index to narrow it.

Assay context

Evidence role

All1,976 Curated comparable37,547 Reported1,976

#	Endpoint	Peptide	Reported value	Assay context	Evidence role	Reference
1	AUC Exposure / Absorption	ATLPC0019880	< 166,500 ng*h/mL	AUC (0 to 24 hrs) in candidiasis patient at 8 mg/kg, iv by HPLChumaniv	Reported	Open
2	AUC Exposure / Absorption	ATLPC0019880	< 166,500 ng*h/mL	AUC (0 to 24 hrs) in candidiasis patient at 10 mg/kg, iv by HPLChumaniv	Reported	Open
3	AUC Exposure / Absorption	ATLPC0019880	< 166,500 ng*h/mL	AUC (0 to 24 hrs) in candidiasis patient at 12 mg/kg, iv by HPLChumaniv	Reported	Open
4	AUC Exposure / Absorption	ATLPC0015133	Observation Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
5	AUC Exposure / Absorption	ATLPC0009237	Observation Exenatide exposure (AUC) increased proportionally over the therapeutic dose range of 5 to 10 mcg.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
6	AUC Exposure / Absorption	ATLPC0009237	Observation Similar exposure is achieved with SC administration of BYETTA in the abdomen, thigh, or upper arm.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
7	AUC Exposure / Absorption	ATLPC0009758	Observation In 5 patients with severe renal impairment (CrCl<30 mL/minute), the AUC and T 1/2 of teriparatide were increased by 73% and 77%, respectively.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
8	AUC Exposure / Absorption	ATLPC0027686	Observation An approximate 2-fold decrease in total serum clearance of lanreotide, with a consequent 2-fold increase in half-life and AUC was observed.	DailyMed SPL 12.3 Pharmacokinetics label extractionserumhuman	Reported	Open
9	AUC Exposure / Absorption	ATLPC0027686	Observation Single-dose linearity was demonstrated with respect to AUC and C max , and showed high inter-subject variability.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
10	AUC Exposure / Absorption	ATLPC0015302	Observation Therefore, standard pharmacokinetic parameters such as area under the curve (AUC), maximum concentration (C max ), and half-life (t ½ ) cannot be calculated.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
11	AUC Exposure / Absorption	ATLPC0019952	Observation Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
12	AUC Exposure / Absorption	ATLPC0010824	Observation The C max and AUC of teduglutide was dose proportional over the dose range of 0.05 to 0.4 mg/kg (up to 8 times the recommended dose of GATTEX).	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
13	AUC Exposure / Absorption	ATLPC0024280	Observation AUC 0-∞ was equivalent between upper arm and abdomen, and between upper arm and thigh.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
14	AUC Exposure / Absorption	ATLPC0024280	Observation AUC 0-∞ from thigh was 22% lower than that from abdomen.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
15	AUC Exposure / Absorption	ATLPC0024280	Observation After subcutaneous single dose administrations, C max and AUC of liraglutide increased proportionally over the therapeutic dose range of 0.6 mg to 1.8 mg.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
16	AUC Exposure / Absorption	ATLPC0011948	Observation Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
17	AUC Exposure / Absorption	ATLPC0011948	Observation Effect of Semaglutide Tablet Formulations : There were no clinically significant differences observed in the mean steady state AUC 0-24h,SS and C max,SS between the 3 mg, 7 mg and 14 mg doses of RYBELSUS and the 1.5 mg, 4 mg and 9 mg doses of OZEMPIC tablets, respectively, in a clinical study conducted in healthy subjects.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
18	AUC Exposure / Absorption	ATLPC0011948	Observation Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
19	AUC Exposure / Absorption	ATLPC0005195	Observation Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
20	AUC Exposure / Absorption	ATLPC0005195	Observation Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open

1–20 / 1,976

Measurements

Browse by ADMET domain

All evidence